Get the Stockscreener App
4.315
0.82%
0.035
After Hours:
4.30
-0.015
-0.35%
Briacell Therapeutics Corp stock is traded at $4.315, with a volume of 139.99K.
It is up +0.82% in the last 24 hours and up +14.46% over the past month.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
See More
Previous Close:
$4.28
Open:
$4.34
24h Volume:
139.99K
Relative Volume:
0.49
Market Cap:
$37.54M
Revenue:
-
Net Income/Loss:
$-30.98M
P/E Ratio:
-0.3534
EPS:
-12.2116
Net Cash Flow:
$-31.84M
1W Performance:
+2.49%
1M Performance:
+14.46%
6M Performance:
+6.54%
1Y Performance:
-59.71%
1-Day Range:
$4.17
$4.3668
1-Week Range:
$3.9245
$4.43
52-Week Range:
$2.60
$14.68
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
4.315 | 37.54M | 0 | -30.98M | -31.84M | -12.21 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
BriaCell Therapeutics Corp. (TSX:BCT): Immunotherapy Pipeline Progress and Clinical Momentum Drive Renewed Investor Confidence - kalkine.ca
Stocks in play: Medicenna Therapeutics Corp. - Yahoo! Finance Canada
BriaCell Therapeutics Warrant (BCTXL) Retreats 11.3% as Traders Test Support Near $0.97Factor Rotation - siam.in
Q&A: Advancing cancer biotech therapies with a multipronged approach - Digital Journal
Why Did BriaCell Therapeutics (TSX:BCT) Surge 18.876% on 17 September 2026? - kalkine.ca
BriaCell (BCTXZ) Rallies +1.01% as Bulls Target $0.16 2026-09-17ETF Premium Discount - siam.in
BriaCell (BCTX) Jumps +5.06% — Is Institutional Money Flowing In? 2026-09-17Butterfly Setup - dars.gov.et
BriaCell phase 3 breast cancer study gets seventh DSMB approval By Investing.com - Investing.com Nigeria
BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Mark - GuruFocus
Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study - Investing News Network
BriaCell phase 3 breast cancer study gets seventh DSMB approval - Investing.com
BriaCell Therapeutics Receives Seventh Consecutive Positive DSMB Recommendation for Phase 3 Metastatic Breast Cancer Study - kalkine.ca
Price to sales forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXL - TradingView
Price to earnings forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXL - TradingView
Enterprise value to revenue forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXL - TradingView
(BCT) Market Dynamics and Trading Signals (BCT:CA) - Stock Traders Daily
Price to book forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXL - TradingView
Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer - marketscreener.com
Equity in earnings of BriaCell Therapeutics Corp – HAM:8BT - TradingView
Book value per share of BriaCell Therapeutics Corp – HAM:8BT - TradingView
BriaCell Therapeutics Corp. (TSX:BCT) Advances as Immunotherapy Pipeline Progress and Clinical Momentum Drive Investor Optimism - kalkine.ca
Net income before discontinued operations of BriaCell Therapeutics Corp – HAM:8BT - TradingView
Free float of BriaCell Therapeutics Corp – HAM:8BT - TradingView
Nature Medicine features a BriaCell trial among 11 shaping medicine in 2026 - Stock Titan
BriaCell Therapeutics (BCTX) Edges Higher as Shares Hold Above Key Support at $3.42Volatility Breakout Picks - dars.gov.et
(BCT) Strategic Equity Report (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp (BCTXW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BriaCell Therapeutics Corp (BCTXW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Briacell Therapeutics Corp (BCTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Enterprise value to revenue forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
Briacell Therapeutics Corp (BCTX) Peer Comparison – Compare with Others - Value Research
Briacell Therapeutics Corp (BCTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. - marketscreener.com
Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. - marketscreener.com
BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation - Investing News Network
BriaCell Therapeutics Stock Faces Renewed Pressure as Biotech Volatility Tests Investor Conviction - kalkine.ca
BriaCell Therapeutics Corp. (TSX:BCT) Falls 4.24% as Clinical-Stage Risk and Volatility Pressure Sentiment - kalkine.ca
BriaCell Therapeutics Corp (BCTXW) Key Financial Ratios – Valuation, Profitability & More - Value Research
BriaCell Therapeutics Corp (BCTXW) Peer Comparison – Compare with Others - Value Research
Briacell Therapeutics Corp (BCTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BriaCell Therapeutics Stock Falls Sharply: Can TSX:BCT Stabilize After Renewed Biotech Selling Pressure? - kalkine.ca
BriaCell Therapeutics Stock Falls 6.41%: Why TSX:BCT Is in Focus as Breast and Prostate Cancer Pipeline Advances - kalkine.ca
BriaCell Therapeutics Corp. (TSX:BCT) Gains Momentum as Immunotherapy Pipeline Progress Supports Investor Optimism - kalkine.ca
BriaCell Therapeutics (TSX:BCT) Advances 6.6% on a Run of Pipeline Milestones - kalkine.ca
BriaCell in Focus: TSX: BCT Investors Watch Major Immunotherapy Milestones Ahead of Clinical Data - kalkine.ca
BriaCell Therapeutics Stock Slides 13.31%: Can Clinical Execution Overcome Renewed Biotech Pressure? - kalkine.ca
BriaCell stock choppy on melanoma vaccine milestone - Investing.com
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ - Yahoo Finance
BriaCell stock choppy on melanoma vaccine milestone By Investing.com - Investing.com Australia
BriaCell (BCTXZ) Session: Advances 2.54% to $0.10 in Latest Trading; Next Test: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingShort Term Trading Ideas - vinanet.vn
BriaCell (BCTXL) Stock: Trades in a Narrow Directional Range at $1.00 in Latest Trading; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotFibonacci Fan - vinanet.vn
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):